Insulet Corporation
PODD Healthcare Medical - Devices NASDAQ
$237.01
$-3.93 (-1.63%)
Open: $238.43 | High: $238.94 | Low: $233.29 | Prev Close: $240.94
Market Cap: $16.68B
Volume: 1.2M | Avg: 933K
Last updated: March 09, 2026 at 02:04 AMFeatured In
This stock appears in the following dashboards:
Options Activity for PODD
Options Screener Data
| Type | Strike | Expiration | Premium | Premium Yield | Call Vol | Put Vol | P/C Ratio | Rating |
|---|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A% | N/A | N/A | N/A | N/A/10 |
Puts/Calls Activity
| Type | Strike | Expiration | Premium | Volume | ROI % | Breakeven | Delta |
|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A | N/A% | $N/A | N/A |
Investment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 561
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 69.50 |
| P/B Ratio | 11.01 |
| P/S Ratio | 6.16 |
| EPS | $3.41 |
| Beta | 1.44 |
| Shares Outstanding | 70.40M |
| 52-Week High | $354.88 |
| 52-Week Low | $230.05 |
| SMA 50 | $264.49 |
| SMA 200 | $301.74 |
| Next Earnings | May 07, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 71.6% |
| Operating Margin | 17.5% |
| Net Margin | 9.1% |
| ROE | 17.4% |
| ROA | 7.7% |
| Debt/Equity | 0.69 |
| Current Ratio | 2.78 |
| Quick Ratio | 2.11 |
Balance Sheet
| Total Assets | $3.19B |
| Total Liabilities | $1.68B |
| Total Equity | $1.52B |
|
|
|
| Cash | $716.10M |
| Total Debt | $1.05B |
| Net Debt | $334.70M |
Income Statement
| Revenue | $2.71B |
| Gross Profit | $1.94B |
| Operating Income | $473.80M |
| Net Income | $247.10M |
|
|
|
| EBITDA | $586.90M |
| Revenue/Share | $38.49 |
Cash Flow
| Operating CF | $569.30M |
| CapEx | $191.60M |
| Free Cash Flow | $377.70M |
|
|
|
| Book Value/Share | $21.53 |
| Tangible Book/Share | $19.14 |
| Equity/Share | $21.53 |
Technical Indicators
| RSI (14) | 46.37 Neutral |
| MACD |
-6.46
Signal: -6.94
|
| Volatility | 37.79% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | -27.26% |
| Sharpe Ratio | -1.26 Poor |
| Volatility (Ann.) | 31.78% Moderate |
| PODD (1Y) | -27.26% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -40.3% |
Sector Comparison (Healthcare)
| Metric | PODD | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 69.5 | 26.85 | 96% |
| P/B Ratio | 11.01 | -19.73 | 91% |
| ROE (%) | 17.36% | -9.62% | 68% |
| Net Margin (%) | 9.12% | 9.32% | 43% |
| Stock Score | 561 | 543.0 | 55% |
| 1Y Return (%) | -27.26 % | +8.84 % | 14% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PODD | $237.01 | $241.86 | $244.72 | $246.09 | $264.94 | $301.85 | 46.37 | -6.46 | 37.79% | 252893 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the PODD stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| PODD | Securities Fraud Investigation Into Insulet Corporation (PODD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm | Neutral | businesswire.com | Read More |
| PODD | Insulet Corporation (PODD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation | Neutral | businesswire.com | Read More |
| PODD | Securities Fraud Investigation Into Insulet Corporation (PODD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz | Neutral | businesswire.com | Read More |
| PODD | Insulet Corporation (NASDAQ:PODD) Sees Significant Increase in Short Interest | Positive | defenseworld.net | Read More |
| PODD | Insulet recalls some insulin devices in US over leakage risk | Neutral | reuters.com | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-27 | Singh Prem | officer: SVP, Global Operations | SELL | 207 | $246.61 | $51048 |
| 2026-02-27 | Singh Prem | officer: SVP, Global Operations | SELL | 62 | $246.61 | $15290 |
| 2026-02-27 | Cousin Laetitia | officer: SVP, Reg, Quality & Compliance | SELL | 200 | $246.61 | $49322 |
| 2026-02-27 | Cousin Laetitia | officer: SVP, Reg, Quality & Compliance | SELL | 53 | $246.61 | $13070 |
| 2026-02-27 | Budden Lauren | officer: Group VP, CAO and Controller | SELL | 119 | $246.61 | $29347 |
| 2026-02-27 | Budden Lauren | officer: Group VP, CAO and Controller | SELL | 99 | $246.61 | $24414 |
| 2026-02-27 | Kapples John W. | officer: SVP and General Counsel | SELL | 411 | $246.61 | $101357 |
| 2026-02-27 | Kapples John W. | officer: SVP and General Counsel | SELL | 194 | $246.61 | $47842 |
| 2026-02-27 | Benjamin Eric | officer: EVP and COO | SELL | 644 | $246.61 | $158817 |
| 2026-02-27 | Benjamin Eric | officer: EVP and COO | SELL | 268 | $246.61 | $66091 |
Company Information
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
| CEO | Ashley A. McEvoy |
| Employees | 3900 |
| Country | US |
| IPO Date | 2007-05-15 |
| Exchange | NASDAQ |
| Website | https://www.insulet.com |
| Sector | Healthcare |
| Industry | Medical - Devices |
Similar Stocks (Healthcare - Medical - Devices)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category